Computational and immunohistochemical analyses highlight axl as a potential prognostic marker for ovarian cancer patients

Anticancer Research

Volumn 36, Issue 8, 2016, Pages 4155-4163

  Lozneanu, Ludmila ^a,b   Pinciroli, Patrizia ^b   Ciobanu, Delia Apostol ^a   Carcangiu, Maria Luisa ^b   Canevari, Silvana ^b   Tomassetti, Antonella ^b   Cruntu, Irina Draga ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AXL; Gene expression; Immunohistochemistry; Ovarian carcinoma; Prognostic marker

Indexed keywords

AXL PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84991826523     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cancer Facts & Figures, American Cancer Society, Atlanta, Ga, USA, 2013.
2. Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211-224, 2013.
3. Nik NN, Vang R, Shih IeM and Kurman R. J: Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 9: 27-45, 2014.
4. Barter RL, Schramm SJ, Mann GJ and Yang YH: Network-based biomarkers enhance classical approaches to prognostic gene expression signatures. BMC Syst Biol 8: S5, 2014.
5. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau M. M, Earp HS and Liu ET: Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031, 1991.
6. Axelrod H and Pienta KJ: Axl as a mediator of cellular growth and survival. Oncotarget 5: 8818-8852, 2014.
7. Linger RM, Keating AK, Earp HS and Graham DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14: 1073-1090, 2010.
8. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H and Mizuno K: Identification of the product of growth arrestspecific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 271: 30022-30027, 1996.
9. Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De Braud F, Canevari S, Anichini A and Sensi M: A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget 6: 5118-5133, 2015.
10. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS and Wu CW: Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064, 2005.
11. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G and Ullrich A: AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68: 1905-1915, 2008.
12. Jacob AN, Kalapurakal J, Davidson WR, Kandpal G, Dunson N, Prashar Y and Kandpai RP: A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145. Cancer Detect Prev 23: 325-332, 1999.
13. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B and Dahlbäck B: Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15: 4742-4749, 2009.
14. Sun W, Fujimoto J and Tamaya T: Coexpression of Gas6/Axl in human ovarian cancers. Oncology 66: 450-457, 2004.
15. Wu X, Liu X, Koul S, Lee CY, Zhang Z and Halmos B: AXL kinase as a novel target for cancer therapy. Oncotarget 5: 9546-9563, 2014.
16. Chen PX, Li QY and Yang Z: Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann Diagn Pathol 17: 425-429, 2013.
17. Rea K, Pinciroli P, Sensi M, Alciato F, Bisaro B, Lozneanu L, Raspagliesi F, Centritto F, Cabodi S, Defilippi P, Avanzi GC, Canevari S and Tomassetti A: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget 6: 30859-30875, 2015.
18. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE and Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A and Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
20. Kurman RJ, Carcangiu ML, Herrington CS and Young RH: WHO Classification of Tumours of the Female Reproductive Organs (IARC WHO Classification of Tumours). 4th ed. Lyon, IARC Press, 2014.
21. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70: 7570-7579, 2010.
22. Li Y, Jia L, Liu C, Gong Y, Ren D, Wang N, Zhang X and Zhao Y: Axl as a downstream effector of TGF-1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumour Biol 36: 1115-1127, 2014.
23. Graham DK, DeRyckere D, Davies KD and Earp HS: The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14: 769-785, 2014.
24. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R and Brugge JS: Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 124: 2611-2625, 2014.